Cancer Immunology and Oncolytic Virology: Technologies and Global Markets

LONDON, May 8, 2017 /PRNewswire/ --

Highlights
• The global cancer immunotherapy market should reach $96.5 billion by 2021 from $73.0 billion in 2016 at a compound annual growth rate (CAGR) of 5.7%, from 2016 to 2021.
• The US region of the global cancer immunotherapy market is the largest market. The market is expected to grow from


Download the full report: https://www.reportbuyer.com/product/2070062/


$38.8 billion in 2016 to $50.6 billion in 2021 at a CAGR of 5.4% for the period 2016-2021.
• The Japan region of the global cancer immunotherapy market is expected to grow from $6.4 billion in 2016 to $10.1 billion in 2021 at a CAGR of 9.6% for the period 2016-2021.

Goals and Objectives
This report, PHM129B Cancer Immunology and Oncolytic Virology: Technologies and Global Markets, provides an overview of the current and potential global market for cancer immunotherapy and oncolytic virology. This report provides information on most clinically significant types of cancers, with supportive information on historical incidence and mortality trends. It underlines the importance of more effective and personalized treatment options for these diseases.

The objective of this report is to provide a comprehensive analysis of the current state and the future direction of cancer immunotherapy. Additionally, the report also provides information on the current developments in oncolytic virology and introduces the promising products in clinical trials. The conventional treatment paradigms, trends in each market segment, and clinical trials and outcomes are provided along with sales figures and forecasts for cancer immunotherapy and virotherapy products from 2015 through 2021.

In this report, the critical evaluation of the products and markets is based on extensive primary and secondary research from industry sources. The evaluation takes into account regulatory policies as well as demographic and epidemiological factors that strongly influence the oncology market.

Reasons for Doing This Study
The aim of this report is to provide detailed information on the new areas of cancer immunology and immunotherapy. Considering the shortcomings of the current treatment paradigms, immunotherapy has provided ground-breaking improvements in the treatment of different types of cancers. Growing clinical information stresses the importance of immunotherapy in cancer treatment. Immunotherapy addresses the need for more efficacious and flexible treatment strategies for managing the global burden of cancer.

This report focuses on the new and latest types of treatment based on immunology. It also features oncolytic virology, a field that is still in its latency, with budding treatment options that promise clinical value for the treatment and management of cancer.

Intended Audience
This report is a comprehensive study of the global market for immunotherapy and oncolytic virology. It includes statistical analysis of industry-oriented information on available and pipeline drugs; discussion of technological trends; and analysis of market landscape and structure in terms of market size, market segments, and geographical market regions.

This report provides crucial information about market growth in cancer immunotherapy and oncolytic virology as indicated for the most common types of cancers. The in-detail analysis and forecasts of the market will be of interest to the pharmaceutical and biotechnology industries, as well as to healthcare providers and clinical and scientific research institutions. Additional audiences may include investment firms in this sector.

Scope of The Study
The scope of this report covers current cancer immunotherapy markets for most common cancers. The market segments included in this report are therapeutic monoclonal antibodies (with special focus on checkpoint inhibitors), synthetic interleukins, interferons, and colony-stimulating factors; small kinase inhibitors of cancer-related targets; protective and therapeutic cancer vaccines; and adoptive cell therapies.

This report also covers treatments that are in development for late-stage and early-stage oncolytic viruses. Detailed epidemiological information, discussion of incidence and mortality trends, overview of regulatory landscapes, and analysis of market shares for leading products and companies are also included in this report.

Information Sources for the Technology Assessment
Both primary and secondary research were conducted and used in preparing this study. The author of the report conducted a comprehensive literature search from public, private, and government sources, which included company publications, industrial and market reports available in physical or electronic format, academic journals, and other professionally written dedicated sources, as well as company and product literature and industrial databases. Data were obtained through interviews and correspondence with clinical-stage pharmaceutical companies and technical experts in cancer immunology and oncolytic virology.

Cancer immunotherapies were assessed according to preclinical, clinical, and post-marketing data in order to evaluate efficacy, safety, competitive edge, and utilization in the market. The market and the pipeline products were stratified according to product category (based on mechanism of action), indication, and geographical region. These products were then comparatively assessed and interrelated.

The selected regions include the U.S., major markets of Europe (Germany, France, the U.K., Spain, and Italy), and Japan. Other international territories such as the Middle East and North Africa (MENA), Central and South America, and Southeast Asia were categorized as a single region (rest of the world). Major markets such as Canada, Mexico, China, India, Australia, and New Zealand were included under this rest of the world (ROW) category.

Forecasting Methodology
For forecasting, initially the affected populations who have access to diagnosis and treatment in each regional market were estimated using epidemiological and demographic data. Each population was then stratified according to obtained prescription rates for market products.

For each drug, an average annual consumption coefficient was calculated. Finally, the values for the selected population, the average annual drug consumption coefficient, and the unit price of the selected drug were multiplied.
Individual trends; generic competition; patent expirations; in-out licensing; co-marketing and codevelopment agreements; merger and acquisitions; and other market dynamics were taken into consideration during forecasting.

Geographic Breakdown
In this report, the geographic regions considered for market analysis include, and only include:
• U.S.
• Europe
• Japan
• Rest of the World

Summary and Highlights
Cancer is a disease with global implications. There are many different types of cancer, of which the most common types include lung, breast, colon and rectal, stomach, head and neck, prostate, cervical, melanoma, and ovarian cancer, as well as leukemia. Cancer is a genetic disease that is conventionally treated by surgery, radiation therapy, chemotherapy, hormonal therapy, and immunotherapy.

Surgery is the mainstay treatment for all cancers. Usually surgery is complimented with radiation or chemotherapy to ensure the clearance of all residual cancer. Despite the advances in treatment, cancer has great plasticity; therefore, after a certain time the effects of treatment fade and cancer returns with acquired resistance. Combination therapy, using multiple modalities including surgery and pharmaceutical or radiation therapy, improves response to treatment.

Radiation and chemotherapy have many side effects. Biological treatment options provide less impactful treatment of cancer. Immunotherapy is a type of biological therapy and it incorporates elements of the immune system in cancer treatment. The immune system has various types of cells and proteins that detect and act upon signs of a disease or infection by harmful and foreign substances such as microbes, bacteria and viruses. The immune system differentiates the body's own cells and tissues through an evolutionary bar-coding system. This system helps the immune system understand encountered foreign substances as "nonself." Cancer cells are recognized as nonself as well. The immune system monitors the body for cancer and destroys when it detects a malignancy. Cancer cells can avoid being recognized by the immune system and develop resistance through numerous methods.

Since the early 1900s, the connection between cancer and the immune system has caught the attention of various scientists and medical practitioners. Although the early studies were bluntly done without current technological and scientific tools, they nonetheless shed insights leading to the development of the first monoclonal antibodies and to the use of biologically derived synthetic interleukins and interferons. After many decades of research, immunotherapy finally emerged as a fully functional clinical area in the 1990s. Since then, the cancer therapeutics landscape has changed dramatically.

With the stream of product approvals in recent years, the global immunotherapy market has reached its current value. In 2015, the global cancer immunotherapy market hit $65 billion. The current immunotherapy market contains several blockbuster products reaching their end-of-market exclusivities; however, the market is mostly comprised of newly introduced and expensive therapies. In 2016, the market expanded by more than 10% over the previous year, reaching $73 billion. During the period of 2016 through 2021, the global cancer immunotherapy market is forecast to grow by a 5.7% compound annual growth rate (CAGR), reaching $96.5 billion in 2021.

The strongest growth is expected to occur in checkpoint-inhibitor drugs with a 19.4% CAGR during the forecast period. Immunomodulators are anticipated to show the second-highest growth rates among immunotherapy products, with an 8.4% CAGR during the same period. The combined sales from both segments are expected to make up for nearly one-third of the market, with a combined sales value of
$28 billion in 2021. Checkpoint inhibitors are virtually comprised of monoclonal antibodies; however, they are assessed separately due to their immense commercial and clinical significance. Sales from other therapeutic antibodies accrued to $28 billion in 2016, and this value is expected to remain relatively constant through 2021, due to several patent expiries, pressure from anticipated generic entries, and newly introduced classes of drugs expected by 2021.

Download the full report: https://www.reportbuyer.com/product/2070062/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

Related Links

http://www.reportbuyer.com